Literature DB >> 8474162

Human immunodeficiency virus type 1 envelope gp120 is cleaved after incubation with recombinant soluble CD4.

A Werner1, J A Levy.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) infects human CD4+ cells by a high-affinity interaction between its envelope glycoprotein gp120 and the CD4 molecule on the cell surface. Subsequent virus entry into the cells involves other steps, one of which could be cleavage of the gp120 followed by virus-cell fusion. The envelope gp120 is highly variable among different HIV-1 isolates, but conserved amino acid sequence motifs that contain potential proteolytic cleavage sites can be found. Following incubation with a soluble form of CD4, we demonstrate that gp120 of highly purified HIV-1 preparations is, without addition of exogenous proteinase, cleaved most likely in the V3 loop, yielding two proteins of 50 and 70 kDa. The extent of gp120 proteolysis is HIV-1 strain dependent and correlates with the recombinant soluble CD4 sensitivity to neutralization of the particular strain. The origin of the proteolytic activity in the virus preparations remains unclear. The results support the hypothesis that cleavage of gp120 is required for HIV infection of cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8474162      PMCID: PMC237577     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

1.  Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein.

Authors:  J D Lifson; M B Feinberg; G R Reyes; L Rabin; B Banapour; S Chakrabarti; B Moss; F Wong-Staal; K S Steimer; E G Engleman
Journal:  Nature       Date:  1986 Oct 23-29       Impact factor: 49.962

2.  Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization.

Authors:  J A McKeating; A McKnight; J P Moore
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

3.  Differential susceptibility to the acquired immunodeficiency syndrome retrovirus in cloned cells of human leukemic T-cell line Molt-4.

Authors:  R Kikukawa; Y Koyanagi; S Harada; N Kobayashi; M Hatanaka; N Yamamoto
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

4.  Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2).

Authors:  R Sanchez-Pescador; M D Power; P J Barr; K S Steimer; M M Stempien; S L Brown-Shimer; W W Gee; A Renard; A Randolph; J A Levy
Journal:  Science       Date:  1985-02-01       Impact factor: 47.728

5.  AIDS retrovirus (ARV-2) clone replicates in transfected human and animal fibroblasts.

Authors:  J A Levy; C Cheng-Mayer; D Dina; P A Luciw
Journal:  Science       Date:  1986-05-23       Impact factor: 47.728

6.  Binding of the human retrovirus HTLV-III/LAV/ARV/HIV to the CD4 (T4) molecule: conformation dependence, epitope mapping, antibody inhibition, and potential for idiotypic mimicry.

Authors:  J S McDougal; J K Nicholson; G D Cross; S P Cort; M S Kennedy; A C Mawle
Journal:  J Immunol       Date:  1986-11-01       Impact factor: 5.422

7.  T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV.

Authors:  D Klatzmann; E Champagne; S Chamaret; J Gruest; D Guetard; T Hercend; J C Gluckman; L Montagnier
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

8.  Characterization of the AIDS-associated retrovirus reverse transcriptase and optimal conditions for its detection in virions.

Authors:  A D Hoffman; B Banapour; J A Levy
Journal:  Virology       Date:  1985-12       Impact factor: 3.616

9.  Molecular cloning of AIDS-associated retrovirus.

Authors:  P A Luciw; S J Potter; K Steimer; D Dina; J A Levy
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

10.  HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope.

Authors:  S D Putney; T J Matthews; W G Robey; D L Lynn; M Robert-Guroff; W T Mueller; A J Langlois; J Ghrayeb; S R Petteway; K J Weinhold
Journal:  Science       Date:  1986-12-12       Impact factor: 47.728

View more
  19 in total

1.  Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants.

Authors:  P Kolchinsky; E Kiprilov; J Sodroski
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

2.  Structure of a V3-containing HIV-1 gp120 core.

Authors:  Chih-chin Huang; Min Tang; Mei-Yun Zhang; Shahzad Majeed; Elizabeth Montabana; Robyn L Stanfield; Dimiter S Dimitrov; Bette Korber; Joseph Sodroski; Ian A Wilson; Richard Wyatt; Peter D Kwong
Journal:  Science       Date:  2005-11-11       Impact factor: 47.728

3.  Characterization of the multiple conformational States of free monomeric and trimeric human immunodeficiency virus envelope glycoproteins after fixation by cross-linker.

Authors:  Wen Yuan; Jessica Bazick; Joseph Sodroski
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

4.  A V3 loop-dependent gp120 element disrupted by CD4 binding stabilizes the human immunodeficiency virus envelope glycoprotein trimer.

Authors:  Shi-Hua Xiang; Andrés Finzi; Beatriz Pacheco; Kevin Alexander; Wen Yuan; Carlo Rizzuto; Chih-Chin Huang; Peter D Kwong; Joseph Sodroski
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

5.  Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops.

Authors:  P Kolchinsky; E Kiprilov; P Bartley; R Rubinstein; J Sodroski
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

6.  The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication.

Authors:  K de Vreese; V Kofler-Mongold; C Leutgeb; V Weber; K Vermeire; S Schacht; J Anné; E de Clercq; R Datema; G Werner
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

7.  Evidence that the structural conformation of envelope gp120 affects human immunodeficiency virus type 1 infectivity, host range, and syncytium-forming ability.

Authors:  L Stamatatos; C Cheng-Mayer
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

8.  Differential regulation of cellular tropism and sensitivity to soluble CD4 neutralization by the envelope gp120 of human immunodeficiency virus type 1.

Authors:  L Stamatatos; A Werner; C Cheng-Mayer
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

9.  Exposure of p19 matrix protein of human T-cell leukemia virus type I (HTLV-I) on the surface of MOLT-4#8 cells after virus adsorption.

Authors:  H Akari; M J Kuroda; T Shinjo; M A el-Farrash; S Harada
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

10.  Inhibition of human immunodeficiency virus infection by agents that interfere with thiol-disulfide interchange upon virus-receptor interaction.

Authors:  H J Ryser; E M Levy; R Mandel; G J DiSciullo
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.